858.450.2800info@Sudoscan.com
SUDOSCAN® User LOGIN
Screening for cardiovascular autonomic neuropathy using SUDOSCAN® Passer au contenu
  • About SUDOSCAN®
  • Our Company
  • Research, Media & Events
  • Contact
  • SUDOSCAN® Shop
  • Supplies
  • Se connecter
  • YouTube
Panier


Sous-total
$0.00
Les codes promo, les frais d'envoi et les taxes seront ajoutés à la caisse.
Votre panier est vide.
SUDOSCAN Logo Powered by Withings SUDOSCAN Logo Powered by Withings Sudoscan Logo white SUDOSCAN Logo Powered by Withings
  • About SUDOSCAN®
  • Our Company
  • Research, Media & Events
  • Contact
  • SUDOSCAN® Shop
  • Supplies
Se connecter Panier
Create Account
Schedule an online DEMO

Access Denied
IMPORTANT! If you’re a store owner, please make sure you have Customer accounts enabled in your Store Admin, as you have customer based locks set up with EasyLockdown app. Enable Customer Accounts
Accueil / Research, Media & Events / Screening for cardiovascular autonomic neuropathy using SUDOSCAN®
Cardiac neuropathy · Diabetes · Scientific publications · 18 février, 2023

Screening for cardiovascular autonomic neuropathy using SUDOSCAN®

Screening for cardiovascular autonomic neuropathy using SUDOSCAN®

Screening for Cardiovascular Autonomic Neuropathy with SUDOSCAN®


Yun-Ru Lai, Chih-Cheng Huang, Ben-Chung Cheng, Nai-Wen Tsai, Wen-Chan Chiu, Hsueh-Wen Chang,
Jung-Fu Chen, Cheng-Hsien Lu.
Article title: Feasibility of combining heart rate variability and electrochemical skin conductance as screening and severity evaluation of cardiovascular autonomic neuropathy in type 2 diabetes.
Muscle Nerve. 2021 Apr 1

YR Lai and colleagues from various medical institutions in Taiwan conducted a clinical study to investigate whether combining heart rate variability (HRV) and electrochemical skin conductance (ESC) measured with SUDOSCAN® can improve the accuracy of cardiovascular autonomic neuropathy (CAN) screening and provide a better estimate of CAN severity in patients with type 2 diabetes (T2DM) who had already developed CAN in outpatient clinics. The study involved 90 T2DM patients, and the results showed that those with more severe CAN had higher CAN score values and lower values in feet ESC and HRV (SDNN*) (P<0.0001 and P=0.023, respectively). Multiple linear regression analysis also revealed that feet ESC and SDNN value (P=0.003 and P<0.0001, respectively) were significantly associated with CAN score. Combining HRV and feet ESC improved the diagnostic accuracy of CAN by increasing sensitivity and specificity according to receiver operating characteristic analysis (as shown in a table).

(*SDNN measures the standard deviation of normal RR interval, which is a measure of the time domain of HRV.)

Combining the results of HRV measurement and feet ESC can not only assess, but also quantitatively reflect the progress or improvement of autonomic nerve function (including sympathetic and parasympathetic activity) in patients with type 2 diabetes.

Sensitivity, specificity, and area under the curve using receiver operating characteristic curve analysis for SDNN, feet electrochemical skin conductance, as well as their combinations in predicting cardiovascular autonomic neuropathy

Sensitivity, specificity, and area under the curve using receiver operating characteristic curve analysis for SDNN, feet electrochemical skin conductance
*=p<0.05; **p<0;01; Abbreviation: ROC, receiver operating characteristic; ESC, electrochemical
skin conductance; SDNN standard deviation of normal RR interval
Φ=The positive or negative test results of feet ESC, SDDN, and its combination were according to cut-off value of each test in ROC analysis.
The false negative rate of the diagnosis of CAN by feet ESC, SDNN, and its combination were 40.7% (22/54), 27.8% (15/54) and 18.5% (10/54), respectively.
Keywords: cardiovascular autonomic neuropathy, electrochemical skin conductance, ESC, SUDOSCAN, heart rate variability, HRV.
Article available here.
Partager Partager sur Facebook Tweeter Tweeter sur Twitter Épingler Épingler sur Pinterest

Retour à Research, Media & Events
Invalid password
Enter
Sudoscan Logo

SUDOSCAN® is a privately-owned French medical device company.

Created in June 2005, SUDOSCAN is located in San Diego, CA, USA; the company's corporate headquarters are in Paris, France. We service all of the North and South America, The Middle East, Europe and Asia.

  • YouTube

Sudoscan

  • About SUDOSCAN®
  • Our Company
  • Research, Media & Events
  • Contact
  • SUDOSCAN® Shop
  • Supplies

Shop SUDOSCAN

  • Login
  • Create an account
  • SUDOSCAN® Shop
  • Electrodes

Resources

  • For Patients
  • For Physicians
  • SUDOSCAN® Articles
  • SUDOSCAN® Videos
  • SUDOSCAN® Image Gallery
  • Reimbursement Regulatory

CONTACT INFO:

US TERRITORIES:
SUDOSCAN Inc.
8525 Gibbs Dr. Suite 304
San Diego, CA 92123

Phone: +1 858 450 2800

INTERNATIONAL:
Impeto Medical
2 Rue Maurice Hartmann,
92130 Issy-les-Moulineaux,
France

Phone: +33 (0)7 87 20 32 03
Website: www.impeto-medical.com/

Promotional Communication. The medical devices SUDOSCAN® is cleared by the US Food and Drug Administration (FDA). The test allows screening and monitoring of peripheral autonomic neuropathies. It can be performed in diabetic patients or in patients suffering from neurological diseases involving small fibers damage. As with any diagnostic test, its results must be interpreted in a global context including the clinic and other examinations performed. Please read the user manual instructions carefully. Contact our office for more information. Last update: 05/10/2023

Langue

  • English
  • Français

Devise

  • Canada (CAD $)
  • États-Unis (USD $)
  • American Express
  • Apple Pay
  • Diners Club
  • Discover
  • Google Pay
  • Mastercard
  • Shop Pay
  • Visa
© 2023 SUDOSCAN USA | Autonomic & Sudomotor Testing Device Web Development
Screening for cardiovascular autonomic neuropathy using SUDOSCAN®